Papers

Poster presentations Full bibliography on NCBI ORCID profile

Selected research

Preprints

  • Baugh, AG, Liu, Y, Gonzalez, E, Al-Zubeidy, B, Iyer, M, Lee, AH et al.. A class act: HDAC1- Malat1 regulates MDSC apoptosis and cell cycling to decrease suppression of T cells. bioRxiv. 2026; :. doi: 10.64898/2026.03.23.713743. PubMed PMID:41929180 PubMed Central PMC13041902.

    bioRxiv

  • Gonzalez, E, Kreger, J, Liu, Y, Wu, X, Barbetta, A, Baugh, AG et al.. Cancer systems immunology reveals myeloid-T cell interactions and B cell activation mediate response to checkpoint inhibition in metastatic breast cancer. bioRxiv. 2025; :. doi: 10.1101/2025.06.09.658361. PubMed PMID:40661534 PubMed Central PMC12258997.

    bioRxiv

  • Barbetta, A, Bangerth, S, Lee, JTC, Rocque, B, Roussos Torres, ET, Kohli, R et al.. IMmuneCite: an integrated workflow for analysis of immune enriched spatial proteomic data. Res Sq. 2024; :. doi: 10.21203/rs.3.rs-4571625/v2. PubMed PMID:39041033 PubMed Central PMC11261960.

    Research Square

  • Baugh, AG, Gonzalez, E, Narumi, VH, Kreger, J, Liu, Y, Rafie, C et al.. Mimicking the breast metastatic microenvironment: characterization of a novel syngeneic model of HER2+ breast cancer. bioRxiv. 2024; :. doi: 10.1101/2024.01.25.577282. PubMed PMID:38352476 PubMed Central PMC10862766.

    bioRxiv

  • Lake, KE, Colonetta, MM, Smith, CA, Martinez-Algarin, K, Saunders, K, Mohta, S et al.. Organoid generation from mouse mammary tumors captures the genetic heterogeneity of clinically relevant copy number alterations. bioRxiv. 2023; :. doi: 10.1101/2023.01.29.526141. PubMed PMID:36778256 PubMed Central PMC9915482.

    bioRxiv

Publications

2026

  • Argyris, DG, Ploumaki, I, Argyri, T, Anastasiadou, DP, Karagiannis, NS, Pavlou, MP et al.. Proteomic signatures of adipocyte recruitment in breast cancer. Endocr Relat Cancer. 2026;33 (5):. doi: 10.1530/ERC-25-0361. PubMed PMID:41961754 PubMed Central PMC13147392.

  • Liu, Y, Baugh, AG, Roussos Torres, ET, MacLean, AL. Inference of marker genes of subtle cell state changes via iLR: iterative logistic regression. Bioinformatics. 2026;42 (2):. doi: 10.1093/bioinformatics/btag051. PubMed PMID:41627891 PubMed Central PMC12925251.

2025

  • Jayachandran, P, Elliott, A, Soni, S, Battaglin, F, Mittal, P, Algaze, S et al.. Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer. Oncogene. 2025;44 (30):2565-2573. doi: 10.1038/s41388-025-03484-z. PubMed PMID:40615690 PubMed Central PMC12277178.

  • Jayachandran, P, Deshmukh, SK, Wu, S, Ribeiro, JR, Kang, I, Xiu, J et al.. Association of Androgen Receptor Expression With Tumor Immune Landscape and Treatment Outcomes of Patients With Breast Cancer. JCO Precis Oncol. 2025;9 :e2400459. doi: 10.1200/PO-24-00459. PubMed PMID:40294352 .

  • McDermott, M, Mehta, R, Roussos Torres, ET, MacLean, AL. Modeling the dynamics of EMT reveals genes associated with pan-cancer intermediate states and plasticity. NPJ Syst Biol Appl. 2025;11 (1):31. doi: 10.1038/s41540-025-00512-2. PubMed PMID:40210876 PubMed Central PMC11986130.

  • Barbetta, A, Bangerth, S, Lee, JTC, Rocque, B, Roussos Torres, ET, Kohli, R et al.. Integrated workflow for analysis of immune enriched spatial proteomic data with IMmuneCite. Sci Rep. 2025;15 (1):9394. doi: 10.1038/s41598-025-93060-y. PubMed PMID:40102469 PubMed Central PMC11920390.

2024

  • Falcone, M, Salhia, B, Hughes Halbert, C, Roussos Torres, ET, Stewart, D, Stern, MC et al.. Impact of Structural Racism and Social Determinants of Health on Disparities in Breast Cancer Mortality. Cancer Res. 2024;84 (23):3924-3935. doi: 10.1158/0008-5472.CAN-24-1359. PubMed PMID:39356624 PubMed Central PMC11611670.

  • Shatsky, RA, Trivedi, MS, Yau, C, Nanda, R, Rugo, HS, Davidian, M et al.. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024;30 (12):3737-3747. doi: 10.1038/s41591-024-03267-1. PubMed PMID:39277672 PubMed Central PMC12089997.

  • Khoury, K, Meisel, JL, Yau, C, Rugo, HS, Nanda, R, Davidian, M et al.. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024;30 (12):3728-3736. doi: 10.1038/s41591-024-03266-2. PubMed PMID:39277671 PubMed Central PMC12044543.

  • Iriondo, O, Mecenas, D, Li, Y, Chin, CR, Thomas, A, Moriarty, A et al.. Hypoxic Memory Mediates Prolonged Tumor-Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression. Cancer Res. 2024;84 (19):3141-3157. doi: 10.1158/0008-5472.CAN-23-2028. PubMed PMID:38990731 PubMed Central PMC11444891.

  • Lake, KE, Colonnetta, MM, Smith, CA, Saunders, K, Martinez-Algarin, K, Mohta, S et al.. Digital droplet PCR analysis of organoids generated from mouse mammary tumors demonstrates proof-of-concept capture of tumor heterogeneity. Front Cell Dev Biol. 2024;12 :1358583. doi: 10.3389/fcell.2024.1358583. PubMed PMID:38827528 PubMed Central PMC11140600.

  • Baugh, AG, Gonzalez, E, Narumi, VH, Kreger, J, Liu, Y, Rafie, C et al.. A new Neu-a syngeneic model of spontaneously metastatic HER2-positive breast cancer. Clin Exp Metastasis. 2024;41 (5):733-746. doi: 10.1007/s10585-024-10289-z. PubMed PMID:38717519 PubMed Central PMC11499368.

  • Hsu, R, Al-Zubeidy, B, Flores, D, Nazarian, A, Baugh, A, Gonzalez, E et al.. Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast to liver metastases in breast cancer. Breast Cancer Res Treat. 2024;206 (2):245-259. doi: 10.1007/s10549-024-07295-w. PubMed PMID:38643348 PubMed Central PMC11182800.

  • Xu, L, Saunders, K, Huang, SP, Knutsdottir, H, Martinez-Algarin, K, Terrazas, I et al.. A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response. Cell Rep Med. 2024;5 (5):101511. doi: 10.1016/j.xcrm.2024.101511. PubMed PMID:38614094 PubMed Central PMC11148512.

  • Roussos Torres, ET, Ho, WJ, Danilova, L, Tandurella, JA, Leatherman, J, Rafie, C et al.. Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial. Nat Cancer. 2024;5 (6):866-879. doi: 10.1038/s43018-024-00729-w. PubMed PMID:38355777 PubMed Central PMC11552660.

2023

  • Kreger, J, Roussos Torres, ET, MacLean, AL. Myeloid-Derived Suppressor-Cell Dynamics Control Outcomes in the Metastatic Niche. Cancer Immunol Res. 2023;11 (5):614-628. doi: 10.1158/2326-6066.CIR-22-0617. PubMed PMID:36848523 PubMed Central PMC10155038.

  • Jayachandran, P, Battaglin, F, Strelez, C, Lenz, A, Algaze, S, Soni, S et al.. Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions. Oncogene. 2023;42 (9):627-637. doi: 10.1038/s41388-022-02584-4. PubMed PMID:36650218 PubMed Central PMC9957733.

2022

  • Cornelius, SL, Colonnetta, MM, Lake, KE, Smith, CA, Zhang, YA, Roussos-Torres, ET et al.. Generating and Imaging Mouse and Human Epithelial Organoids from Normal and Tumor Mammary Tissue Without Passaging. J Vis Exp. 2022; (189):. doi: 10.3791/64626. PubMed PMID:36440890 PubMed Central PMC10149050.

  • Battaglin, F, Jayachandran, P, Strelez, C, Lenz, A, Algaze, S, Soni, S et al.. Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatment. Oncogene. 2022;41 (43):4769-4778. doi: 10.1038/s41388-022-02479-4. PubMed PMID:36182970 PubMed Central PMC10591256.

  • Roussos Torres, ET. Revival and Recharacterization of a Preclinical Model of Hormone-Dependent Breast Cancer to Study Immunotherapy. Cancer Immunol Res. 2022;10 (6):672-673. doi: 10.1158/2326-6066.CIR-22-0315. PubMed PMID:35544128 .

  • Sidiropoulos, DN, Rafie, CI, Jang, JK, Castanon, S, Baugh, AG, Gonzalez, E et al.. Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment. Cancer Immunol Res. 2022;10 (5):656-669. doi: 10.1158/2326-6066.CIR-21-0170. PubMed PMID:35201318 PubMed Central PMC9064912.

2021

  • Erbe, R, Wang, Z, Wu, S, Xiu, J, Zaidi, N, La, J et al.. Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell Rep. 2021;37 (7):110033. doi: 10.1016/j.celrep.2021.110033. PubMed PMID:34788629 .

  • Erbe, R, Wang, Z, Wu, S, Xiu, J, Zaidi, N, La, J et al.. Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell Rep. 2021;36 (8):109599. doi: 10.1016/j.celrep.2021.109599. PubMed PMID:34433020 PubMed Central PMC8757482.

  • Goode, EF, Roussos Torres, ET, Irshad, S. Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response. Front Mol Biosci. 2021;8 :674558. doi: 10.3389/fmolb.2021.674558. PubMed PMID:34141724 PubMed Central PMC8205515.

  • Roussos Torres, ET, Rafie, C, Wang, C, Lim, D, Brufsky, A, LoRusso, P et al.. Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). Clin Cancer Res. 2021;27 (21):5828-5837. doi: 10.1158/1078-0432.CCR-20-5017. PubMed PMID:34135021 PubMed Central PMC8563383.

  • Battaglin, F, Chan, P, Pan, Y, Soni, S, Qu, M, Spiller, ER et al.. Clocking cancer: the circadian clock as a target in cancer therapy. Oncogene. 2021;40 (18):3187-3200. doi: 10.1038/s41388-021-01778-6. PubMed PMID:33846572 PubMed Central PMC8549632.

  • Roussos Torres, ET, Epstein, AL. Adopting an alternative structure for clinical trials in immunotherapy. Expert Rev Anticancer Ther. 2021;21 (4):373-375. doi: 10.1080/14737140.2021.1875822. PubMed PMID:33435760 .

2020

  • Mirando, AC, Patil, A, Rafie, CI, Christmas, BJ, Pandey, NB, Stearns, V et al.. Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. Oncoimmunology. 2020;9 (1):1760685. doi: 10.1080/2162402X.2020.1760685. PubMed PMID:32923118 PubMed Central PMC7458646.

  • Sheng, JY, Santa-Maria, CA, Mangini, N, Norman, H, Couzi, R, Nunes, R et al.. Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. JCO Oncol Pract. 2020;16 (10):665-674. doi: 10.1200/OP.20.00364. PubMed PMID:32603252 PubMed Central PMC7564133.

  • Sharma, P, Connolly, RM, Roussos Torres, ET, Thompson, A. Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer. Am Soc Clin Oncol Educ Book. 2020;40 :1-16. doi: 10.1200/EDBK_281381. PubMed PMID:32315235 .

  • Wang, H, Sové, RJ, Jafarnejad, M, Rahmeh, S, Jaffee, EM, Stearns, V et al.. Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. Front Bioeng Biotechnol. 2020;8 :141. doi: 10.3389/fbioe.2020.00141. PubMed PMID:32158754 PubMed Central PMC7051945.

2019

  • Davis-Marcisak, EF, Sherman, TD, Orugunta, P, Stein-O'Brien, GL, Puram, SV, Roussos Torres, ET et al.. Differential Variation Analysis Enables Detection of Tumor Heterogeneity Using Single-Cell RNA-Sequencing Data. Cancer Res. 2019;79 (19):5102-5112. doi: 10.1158/0008-5472.CAN-18-3882. PubMed PMID:31337651 PubMed Central PMC6844448.

  • Ma, HS, Poudel, B, Torres, ER, Sidhom, JW, Robinson, TM, Christmas, B et al.. A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity. Cancer Immunol Res. 2019;7 (3):428-442. doi: 10.1158/2326-6066.CIR-18-0061. PubMed PMID:30642833 PubMed Central PMC6397686.

2018

  • Christmas, BJ, Rafie, CI, Hopkins, AC, Scott, BA, Ma, HS, Cruz, KA et al.. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res. 2018;6 (12):1561-1577. doi: 10.1158/2326-6066.CIR-18-0070. PubMed PMID:30341213 PubMed Central PMC6279584.

2012

  • Gligorijevic, B, Wyckoff, J, Yamaguchi, H, Wang, Y, Roussos, ET, Condeelis, J et al.. N-WASP-mediated invadopodium formation is involved in intravasation and lung metastasis of mammary tumors. J Cell Sci. 2012;125 (Pt 3):724-34. doi: 10.1242/jcs.092726. PubMed PMID:22389406 PubMed Central PMC3367832.

2011

  • Entenberg, D, Wyckoff, J, Gligorijevic, B, Roussos, ET, Verkhusha, VV, Pollard, JW et al.. Setup and use of a two-laser multiphoton microscope for multichannel intravital fluorescence imaging. Nat Protoc. 2011;6 (10):1500-20. doi: 10.1038/nprot.2011.376. PubMed PMID:21959234 PubMed Central PMC4028841.

  • Roussos, ET, Condeelis, JS, Patsialou, A. Chemotaxis in cancer. Nat Rev Cancer. 2011;11 (8):573-87. doi: 10.1038/nrc3078. PubMed PMID:21779009 PubMed Central PMC4030706.

  • Roussos, ET, Balsamo, M, Alford, SK, Wyckoff, JB, Gligorijevic, B, Wang, Y et al.. Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. J Cell Sci. 2011;124 (Pt 13):2120-31. doi: 10.1242/jcs.086231. PubMed PMID:21670198 PubMed Central PMC3113666.

  • Roussos, ET, Goswami, S, Balsamo, M, Wang, Y, Stobezki, R, Adler, E et al.. Mena invasive (Mena(INV)) and Mena11a isoforms play distinct roles in breast cancer cell cohesion and association with TMEM. Clin Exp Metastasis. 2011;28 (6):515-27. doi: 10.1007/s10585-011-9388-6. PubMed PMID:21484349 PubMed Central PMC3459587.

2010

  • Roussos, ET, Wang, Y, Wyckoff, JB, Sellers, RS, Wang, W, Li, J et al.. Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors. Breast Cancer Res. 2010;12 (6):R101. doi: 10.1186/bcr2784. PubMed PMID:21108830 PubMed Central PMC3046446.

  • Roussos, ET, Keckesova, Z, Haley, JD, Epstein, DM, Weinberg, RA, Condeelis, JS et al.. AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res. 2010;70 (19):7360-4. doi: 10.1158/0008-5472.CAN-10-1208. PubMed PMID:20823151 .

2009

  • Pang, H, Flinn, R, Patsialou, A, Wyckoff, J, Roussos, ET, Wu, H et al.. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res. 2009;69 (23):8868-76. doi: 10.1158/0008-5472.CAN-09-1968. PubMed PMID:19903845 PubMed Central PMC2793177.

2008

  • Philippar, U, Roussos, ET, Oser, M, Yamaguchi, H, Kim, HD, Giampieri, S et al.. A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell. 2008;15 (6):813-28. doi: 10.1016/j.devcel.2008.09.003. PubMed PMID:19081071 PubMed Central PMC2637261.

2006

  • Mao, HZ, Roussos, ET, Péterfy, M. Genetic analysis of the diabetes-prone C57BLKS/J mouse strain reveals genetic contribution from multiple strains. Biochim Biophys Acta. 2006;1762 (4):440-6. doi: 10.1016/j.bbadis.2006.01.002. PubMed PMID:16481151 .

2003

  • Ma, MH, Yang, HH, Parker, K, Manyak, S, Friedman, JM, Altamirano, C et al.. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9 (3):1136-44. . PubMed PMID:12631619 .